NATtrol™ SARS Associated Coronavirus 2 Negative Control (6 x 0.5 mL)

ZeptoMetrix external quality controls and verification panels, such as SARS Associated Coronavirus 2 Negative Control (6 x 0.5 mL), have demonstrated performance on a variety of molecular platforms. Based upon the platform and assay’s product configuration, including but not limited to fill volumes and concentrations of analytes, we recommend our NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control to be used in conjunction with the Cepheid® GeneXpert®, Luminex® Aries®, BioFire® FilmArray®, QIAGEN® QIAstat-Dx®, GenMark®ePlex®, or Abbott ID Now™ system or a real-time PCR thermal cycler. NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control includes A549.

• Formulated with purified, intact organisms
• Organisms are chemically modified to render them noninfectious
• Refrigerator stable—store between 2 and 8°C
• Purified protein matrix treated with 0.09% sodium azide
• 6 x 0.5 mL vials
• Target concentration of 50,000 cells/mL

Contact our team today if you have any questions about SARS Associated Coronavirus 2 Negative Control (6 x 0.5 mL).

*Pat.: http://www.zeptometrix.com/patent-information/

NATtrol products are ready-to-use, inactivated full process controls designed to evaluate the performance of molecular tests. They can be used for verification of assays, training of laboratory personnel and to monitor assay-kit lot performance. NATtrol products contain intact organisms and should be run in a manner similar to clinical specimens.

• ENGLISH (PI)
• ENGLISH (SDS)

(SARS-CoV-2) Negative Control (6 x 0.5 mL) is for research use only. Not for use in diagnostic procedures. Quality control materials should be used in accordance with local, state, federal, and accreditation requirements. This product is not intended to replace the manufacturer's controls provided with the assay. Propagation or commercialization are prohibited without prior written consent from Antylia Scientific.

When used as a control for nucleic acid tests, the same protocols as those used to amplify extracted clinical specimens should be employed.

The suitability and performance characteristics should be determined by your laboratory for each intended usage.